Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the EU / 2025-524602-15-00
Authorised, recruiting Phase II

Diving into the noradrenergic system : Role of the alpha2C-adrenergic receptors NA2C-TEP-IRM

2025-524602-15-00 · tracked via the Priya Life Science EU tracker
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Nervous System Diseases
Decision date
24/04/2026
Enrollment target
165
Sites
France

Condition studied

Neurology

Investigational medicinal product(s)

[11C]ORM-13070

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

Derived from the PET data, the binding potential (BPND) parametric maps will be calculated using compartmental modelling techniques. Derived from the MRI data, the LC will be defined with a semi-automatic method from the MRI sequence sensitive to neuromelanin, and its signal intensity will be calculated for each participant as previously described (Laurencin et al., 2024a)

Endpoint detail

Correlation coefficients between regional BPND and contrast ratio in the LC (signal intensity)., Correlation coefficients between PET-MRI indices of the noradrenergic system (α₂C BPND and contrast ratio in the LC) and performance: · cognitive: MoCA, TMT A/B, Stroop; · memory: RL/RI-16, digit memory (span); · Language: verbal fluency; · Visuospatial: VOSP score; · Olfactory: Sniffin' Sticks (TDI score); · Affective/Mood: apathy (LARS), depression (BDI-II), anxiety (STAI), fatigue (PDFS-16), impulsivity (UPPS) · Sleep: Epworth, RBDSQ; · Dysautonomic: SCOPA-AUT score; · Pain (EVA score), Correlation coefficients between PET-MRI indices of the noradrenergic system (α₂C BPND and contrast ratio in the LC) and clinical and behavioral variables: Disease severity; Cognition; Memory; Language; Visuospatial ability; Olfactory, Affective/Mood; Sleep ; Dysautonomia ; Pain

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524602-15-00 on CTIS ↗ ← All trials in the EU